FDA approves first AI-assisted lung testing product

The U.S. Food and Drug Administration (FDA) recently approved the AI-assisted lung testing product of Zhongguancun enterprise Beijing Infervision Technology Co.

It is the first FDA-approved auxiliary lung testing product based on deep learning.

As lung cancer cases increase year by year, the Lung Cancer Screening (LCS) program was launched in the U.S., which provides early screening for people with high risk of lung cancer who are currently asymptomatic.

The program has been included in the medical insurance system by the Centers for Medicare and Medicaid Services (CMS).

Infervision is one of the first companies in China to apply artificial intelligence to medical imaging.

The company has cooperated with many top medical institutions in North America, including the University of Maryland Medical Center and Thomas Jefferson University Hospitals.

Having obtaining FDA marketing approval, Infervision AI can not only conduct business cooperation with 1700+ ACR members that provide LCS services, including hospitals, imaging centers, and front-end and back-end companies, but also provide AI-assisted lung disease screening for various medical institutions and imaging centers in North America.

Since the end of February of this year, Infervision has successively obtained EU CE certification, Japan PMDA certification, and US FDA certification, becoming the focus of the global medical AI industry.

As of May this year, Infervision had completed a strategic layout of 33 provincial administrative regions in China, North America, Asia-Pacific and Europe.

Now the medical AI services of Infervision are offered in 10 countries around the world, with an average daily AI quality control operation of 55,000+ cases and more than19 million completed cases.